Johnson & Johnson (JNJ) Q2 2025 Earnings
How Did JNJ Stock React to Q2 2025 Earnings?
S&P 500 over the same 30 days: +3.08%.
Did JNJ Beat Earnings? Q2 2025 Results
Yes. Johnson & Johnson reported Q2 2025 earnings of $2.77 a share on Jul 16, 2025, beating the $2.68 consensus estimate by 3.4%. Revenue was $23.7B against a $22.9B estimate.
Johnson & Johnson capped a strong second quarter with results that cleared Wall Street's bar on both the top and bottom lines, as the healthcare giant's diversified portfolio proved resilient even in the face of meaningful headwinds. Adjusted diluted EPS came in at $2.77, beating the $2.68 consensus by 3.43%, while revenue climbed 5.8% year over year to $23.74 billion, topping expectations of $22.86 billion by 3.88%. The driving force behind the beat was a powerful oncology surge within its Innovative Medicine segment — led by DARZALEX at $3.54 billion and ERLEADA growing 23.4% — which helped absorb a 42.7% decline in STELARA as biosimilar competition continued to erode that franchise. MedTech contributed meaningfully as well, with cardiovascular growing 23.5% on the strength of <a href="https://247wallst.com/investing/2025/07/16/johnson-johnson-nyse-jnj-live-earnings-updates-will-the-dividend-champion-deliver/">electrophysiology and structural heart</a> products. Management backed the momentum by raising full-year 2025 guidance, lifting the adjusted EPS midpoint by $0.25 to $10.85 and increasing expected reported sales growth to approximately 5.4%.
- DARZALEX worldwide sales growth of 23.0% driven by oncology demand
- CARVYKTI rapid ramp contributing $439M in Q2 worldwide sales
- TREMFYA growth of 31.0% driven by immunology expansion including ulcerative colitis
- SPRAVATO growth of 53.3% in neuroscience
- ERLEADA growth of 23.4% in prostate cancer
- MedTech Cardiovascular growth of 23.5% driven by electrophysiology, Abiomed, and Shockwave
- Intra-Cellular Therapies acquisition adding CAPLYTA with $211M in first quarter contribution
- Favorable foreign exchange contributing 1.2 percentage points to total reported growth
“Today's strong results reflect the depth and strength of Johnson & Johnson's uniquely diversified business operating across both MedTech and Innovative Medicine.”
Johnson & Johnson CEO, on the earnings call
What Was Johnson & Johnson's Outlook in Q2 2025?
Johnson & Johnson raised its full-year 2025 guidance, increasing reported sales growth at the midpoint by $2 billion to approximately 5.4% (excluding COVID-19 Vaccine), and increasing full-year adjusted EPS guidance by $0.25 to $10.85. Adjusted operational EPS was increased to $10.68 at the midpoint. The company expects elevated growth in the second half of 2025, driven by anticipated game-changing approvals and submissions in lung and bladder cancer, major depressive disorder, psoriasis, surgery, and cardiovascular. Currency assumptions use Euro average rate of $1.13 for July 2025.
JNJ YoY Financials
| Metric | Q2 2025 | Q2 2024 | Year over year |
|---|---|---|---|
| Revenue | $23.7B | $22.4B | +5.8% |
| Gross Profit | $16.1B | $15.6B | +3.5% |
| Net Income | $5.5B | $4.7B | +18.2% |
| Operating Income | $6.5B | $6.7B | −2.5% |
JNJ Revenue by Segment
JNJ Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.